Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $34.00 Price Target at Wedbush

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its price objective reduced by investment analysts at Wedbush from $35.00 to $34.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a "neutral" rating on the biopharmaceutical company's stock. Wedbush's price target indicates a potential upside of 22.73% from the company's current price. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.66) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($1.46) EPS, FY2027 earnings at ($1.49) EPS, FY2028 earnings at $0.31 EPS and FY2029 earnings at $1.87 EPS.

Other analysts have also issued reports about the company. William Blair initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective for the company. Guggenheim reissued a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Piper Sandler cut their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. JPMorgan Chase & Co. boosted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Finally, Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $83.64.

Ultragenyx Pharmaceutical Trading Up 1.4%

NASDAQ RARE traded up $0.39 during trading on Monday, reaching $27.70. 934,371 shares of the company's stock were exchanged, compared to its average volume of 957,050. The firm has a market capitalization of $2.62 billion, a PE ratio of -4.72 and a beta of 0.26. Ultragenyx Pharmaceutical has a fifty-two week low of $26.85 and a fifty-two week high of $60.37. The company's fifty day simple moving average is $36.00 and its 200-day simple moving average is $38.46.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The company had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.03) earnings per share. Equities analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares in the company, valued at approximately $573,712.16. The trade was a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 3,167 shares of company stock valued at $118,824 in the last 90 days. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 613,633 shares of the biopharmaceutical company's stock worth $25,816,000 after acquiring an additional 19,112 shares during the period. Raymond James Financial Inc. bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $916,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Ultragenyx Pharmaceutical by 28.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,874 shares of the biopharmaceutical company's stock valued at $962,000 after purchasing an additional 5,104 shares in the last quarter. Swiss National Bank grew its stake in shares of Ultragenyx Pharmaceutical by 2.5% in the 4th quarter. Swiss National Bank now owns 163,152 shares of the biopharmaceutical company's stock valued at $6,864,000 after purchasing an additional 4,000 shares during the period. Finally, Xponance Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 8.3% in the 4th quarter. Xponance Inc. now owns 12,205 shares of the biopharmaceutical company's stock valued at $513,000 after purchasing an additional 940 shares during the period. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.